A Murinized Bimagrumab Analogue Increases Skeletal Muscle Mass and Improves Cardiometabolic Remodelling in Experimental Hypertrophic Cardiomyopathy.
BACKGROUND
Hypertrophic cardiomyopathy (HCM) involves left ventricular hypertrophy and metabolic dysfunction. Given the role of skeletal muscle in systemic metabolism, we investigated whether activin type II receptor inhibition with CDD866, a murinized bimagrumab analogue that induces skeletal muscle hypertrophy, improves physical...
